Skip to content

Bioalmanac

CJC-1295

Modified GRF (1-29) · CJC-1295 no DAC · Sermorelin analogue

Early human trials

Status reviewed 12 Aug 2026

Prohibited in sport

A GHRH analogue that raises growth hormone by amplifying the body's own release signal. Sold in two forms whose durations differ by two orders of magnitude.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 5 mg vial, 100 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL5 mg/mL0.02 mL2 units50
2 mL2.5 mg/mL0.04 mL4 units50
3 mL1.667 mg/mL0.06 mL6 units50
5 mL1 mg/mL0.1 mL10 units50

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Non-DAC, commonly described100–300 mcgOne to three times dailyCommunity practice
With DAC, commonly described1000–2000 mcgOnce or twice weeklyCommunity practice

When to stop

  • Persistent numbness, tingling or wrist pain, which can indicate fluid-related nerve compression.
  • Noticeable swelling of the hands, feet or face.
  • Unusual thirst, frequent urination or blurred vision, which can indicate raised blood glucose.
  • Any new lump or growth. Raised IGF-1 promotes cell proliferation, so investigate it instead of watching it.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Not approved for human use in the United States. The FDA has identified CJC-1295 as a substance raising concerns for use in compounded preparations. Sold only as a research chemical.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/cjc-1295

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.